Medicus Sciences Acquisition Corp. (NASDAQ:MSAC) filed an 8-K this morning disclosing that it has signed a non-binding letter of intent (LOI) for a potential business combination with medical technology company Anteris Technologies Ltd (“Anteris”), but did not provide any other details.
Australia-based Anteris is a structural heart company helping healthcare professionals to create life-changing outcomes for patients through its Better Science and Better Design technologies.
SPACs are not typically obligated to disclose discussions at this stage. However, in Anteris’ case, it was required to make a public announcement disclosing that it had been approached by the company due to applicable Australian securities laws.
This is not the same as a definitive agreement (DA) and Medicus Sciences will remain in our “searching” column until a DA is actually singed and announced. There is no guarantee that the parties will come to an agreement on a definitive merger and we have seen LOIs announced in the past only for the SPAC to sign a DA with a different target weeks later.
Medicus has a little over a year left to find a target with a deadline of February 18, 2023, giving it plenty of time to sign a DA.
With the passage this weekend of $95 billion in funding for Ukraine, Israel and Taiwan by the House of Representatives, some focus has gone back towards the defense sector, which has generally had a good year as a whole. But, SPACs have not been as active in defense, despite the fact that companies in the...
At the SPAC of Dawn As April’s sleepy month for SPAC news continues, there is only one special meeting on the docket to consider a SPAC deal approval, that being today’s vote on Pegasus Digital Mobility‘s (NYSE:PGSS) combination with equipment manufacturer Schmid. Three more SPACs are facing extension votes this week, including Pyrophyte (NYSE:PHYT), whose...
Terms Tracker for the Week Ending April 19, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Passover and school spring break starts next week, which most likely means a slowdown in SPAC filing activity. Although Churchill IX is now rumored to...
Despite a week of general pull-backs in the market, fintech firm Ibotta (NYSE:IBTA) nonetheless took the dive and had a good week debuting via a traditional IPO in the choppy waters. The company, which provides app-based consumer cashback discounts on purchases, priced its IPO at $88, above its proposed range of $76 to $84, and...
At the SPAC of Dawn Happy Friday! SPACInsider has unveiled new presets on SPAC Performance accessible via the Data drop-down to easily sort for the highest and lowest performing active SPACs and de-SPACs. On the de-SPAC side, Vertiv (NYSE:VRT) continues to be well ahead of the pack, logging a 710% return by share price adjusted...